Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
SYN's Cash to Debt is ranked higher than
93% of the 895 Companies
in the Global Biotechnology industry.

( Industry Median: 27.79 vs. SYN: No Debt )
Ranked among companies with meaningful Cash to Debt only.
SYN' s Cash to Debt Range Over the Past 10 Years
Min: 0.02  Med: 10000.00 Max: No Debt
Current: No Debt
Interest Coverage No Debt
SYN's Interest Coverage is ranked higher than
90% of the 410 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SYN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
SYN' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 2
Z-Score: -1.62
M-Score: -8.36
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -820.99
SYN's ROE (%) is ranked lower than
98% of the 807 Companies
in the Global Biotechnology industry.

( Industry Median: -31.22 vs. SYN: -820.99 )
Ranked among companies with meaningful ROE (%) only.
SYN' s ROE (%) Range Over the Past 10 Years
Min: -187.95  Med: -87.71 Max: -48.04
Current: -820.99
-187.95
-48.04
ROA (%) -213.07
SYN's ROA (%) is ranked lower than
94% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. SYN: -213.07 )
Ranked among companies with meaningful ROA (%) only.
SYN' s ROA (%) Range Over the Past 10 Years
Min: -163.34  Med: -79.33 Max: -41.8
Current: -213.07
-163.34
-41.8
ROC (Joel Greenblatt) (%) -15350.63
SYN's ROC (Joel Greenblatt) (%) is ranked lower than
91% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -378.42 vs. SYN: -15350.63 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SYN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -6156.76  Med: -849.56 Max: -112.64
Current: -15350.63
-6156.76
-112.64
EBITDA Growth (3Y)(%) 16.30
SYN's EBITDA Growth (3Y)(%) is ranked higher than
74% of the 454 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. SYN: 16.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SYN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -31.15 Max: 108
Current: 16.3
0
108
EPS Growth (3Y)(%) 5.20
SYN's EPS Growth (3Y)(%) is ranked higher than
62% of the 462 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. SYN: 5.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SYN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -31.90 Max: 65.1
Current: 5.2
0
65.1
» SYN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

SYN Guru Trades in Q3 2014

Chuck Royce 276,000 sh (unchged)
» More
Q4 2014

SYN Guru Trades in Q4 2014

Chuck Royce Sold Out
» More
Q3 2015

SYN Guru Trades in Q3 2015

Ken Fisher 10,500 sh (New)
» More
Q4 2015

SYN Guru Trades in Q4 2015

Ken Fisher 10,500 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with SYN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.11
SYN's P/B is ranked lower than
76% of the 1122 Companies
in the Global Biotechnology industry.

( Industry Median: 2.68 vs. SYN: 4.11 )
Ranked among companies with meaningful P/B only.
SYN' s P/B Range Over the Past 10 Years
Min: 1.52  Med: 5.35 Max: 10.53
Current: 4.11
1.52
10.53
Current Ratio 2.44
SYN's Current Ratio is ranked lower than
69% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. SYN: 2.44 )
Ranked among companies with meaningful Current Ratio only.
SYN' s Current Ratio Range Over the Past 10 Years
Min: 0.03  Med: 5.76 Max: 58.44
Current: 2.44
0.03
58.44
Quick Ratio 2.44
SYN's Quick Ratio is ranked lower than
65% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.43 vs. SYN: 2.44 )
Ranked among companies with meaningful Quick Ratio only.
SYN' s Quick Ratio Range Over the Past 10 Years
Min: 0.03  Med: 5.76 Max: 58.44
Current: 2.44
0.03
58.44

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.76
SYN's Price/Net Cash is ranked lower than
55% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: 6.04 vs. SYN: 6.76 )
Ranked among companies with meaningful Price/Net Cash only.
SYN' s Price/Net Cash Range Over the Past 10 Years
Min: 0.72  Med: 9.17 Max: 44.5
Current: 6.76
0.72
44.5
Price/Net Current Asset Value 4.11
SYN's Price/Net Current Asset Value is ranked higher than
57% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: 6.40 vs. SYN: 4.11 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SYN' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.72  Med: 8.15 Max: 29.67
Current: 4.11
0.72
29.67
Price/Tangible Book 4.11
SYN's Price/Tangible Book is ranked lower than
52% of the 1048 Companies
in the Global Biotechnology industry.

( Industry Median: 4.12 vs. SYN: 4.11 )
Ranked among companies with meaningful Price/Tangible Book only.
SYN' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.56  Med: 7.52 Max: 29.67
Current: 4.11
0.56
29.67
Earnings Yield (Greenblatt) (%) -51.03
SYN's Earnings Yield (Greenblatt) (%) is ranked lower than
80% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. SYN: -51.03 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SYN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -51.03  Med: 0.00 Max: 0
Current: -51.03
-51.03
0

More Statistics

Revenue(Mil) $3
EPS $ -0.57
Beta0.94
Short Percentage of Float12.94%
52-Week Range $1.11 - 4.32
Shares Outstanding(Mil)90.81

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil)
EPS($) -0.55 -0.58 -0.70 -0.88
EPS without NRI($) -0.55 -0.58 -0.70 -0.88

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:SFYB.Germany,
Synthetic Biologics Inc was incorporated in 1986 as Sheffield Pharmaceuticals, Inc. The Company is a biotechnology company focused on the development of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases. Its developing an oral treatment to reduce the impact of methane producing organisms on constipation-predominant irritable bowel syndrome or C-IBS, an oral biologic to protect the gastrointestinal or GI microflora from the effects of intravenous or IV antibiotics for the prevention of Clostridium difficile or C. diff infection, a series of monoclonal antibodies or mAbs for the treatment of Pertussis and Acinetobacter infections, and a biologic targeted at the prevention and treatment of a root cause of a subset of IBS. In addition, it has two legacy programs. Its developing an oral estriol drug for the treatment of relapsing-remitting multiple sclerosis or MS and cognitive dysfunction in MS. It also partnered the development of a treatment for fibromyalgia. Trimesta or oral estriol is being developed as an oral once-daily treatment for relapsing-remitting MS in women. Trimesta is also being developed for the treatment of cognitive dysfunction in female MS patients. This 12-month randomized, double-blind, placebo-controlled Phase II clinical trial is being conducted at UCLA. There are nine FDA-approved therapies for the treatment of relapsing-remitting MS: Betaseron, Rebif, Avonex, Copaxone, Tysabri, Gilenya, Extavia, Aubagio and Tecfidera. Effirma or flupirtine is being developed for the treatment of fibromyalgia by Meda AB. Current FDA-approved therapies for the treatment of C-IBS include AMITIZA or lubiprostone and LINZESS or linaclotide. The Company utilizes contract manufacturing firms to produce its investigational products Trimesta and SYN-004 in accordance with current good manufacturing processes or cGMP guidelines outlined by the FDA. It competes with Actelion Pharmaceuticals, Bayer Health Care, Biogen Idec, Eli Lilly & Co., Genzyme, GlaxoSmithKline Pharmaceuticals, Merck & Co., Pfizer, Novartis, Teva Pharmaceuticals and United Therapeutics, among others. The Company is subject to various government FDA, FTC, CPSC and USDA regulations.
» More Articles for SYN

Headlines

Articles On GuruFocus.com
Synodon Inc. – A Breakthrough Technology For Pipeline Safety Jan 28 2013 

More From Other Websites
Synthetic Biologics Tanks on Unfavorable Trimesta Data Feb 03 2016
Synthetic Biologics to Present at the 2016 BIO CEO & Investor Conference Feb 03 2016
Synthetic Biologics Crashes Following Disappointing Phase 2 Results Feb 02 2016
SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement,... Feb 02 2016
Synthetic Biologics Reports Results of Independent Third Party Evaluations of Trimesta™ Data from... Feb 02 2016
Synthetic Biologics Posts Encouraging Data on SYN-010 Jan 20 2016
4 Stocks That Are Trading Higher In The Face of the Down Market Today Jan 20 2016
Synthetic Biologics Surges 25% Amid Positive Phase 2 Data Jan 20 2016
Synthetic Biologics Reports Positive Topline Data from Second Phase 2 Clinical Trial of SYN-010 in... Jan 19 2016
Synthetic Biologics Reports Positive Topline Data from Second Phase 2 Clinical Trial of SYN-010 in... Jan 19 2016
SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jan 11 2016
Edited Transcript of SYN earnings conference call or presentation 5-Nov-15 9:30pm GMT Jan 08 2016
12 Biotechs With Binary Events Coming This Year Jan 08 2016
Synthetic Biologics to Present at the Biotech Showcase™ 2016 Conference Jan 06 2016
Synthetic Biologics to Present at the Biotech Showcase™ 2016 Conference Jan 06 2016
[$$] Monsanto's Shares: Engineered for Growth Dec 19 2015
Timing is Crucial, Upside Analysis - Analyst Notes on Mercury Systems, Synthetic Biologics, CRA... Dec 15 2015
Promising Clinical Trials Coming in 2016 for IBD, Prostate Cancer and Spinal Cord Injuries Dec 15 2015
SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial... Dec 11 2015
Synthetic Biologics Targeting IBS Cause, Not Just Treatment Dec 10 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK